Metropolitan Life Insurance Company (MetLife)’s IGM Biosciences IGMS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-749	Closed	-$7.23K	–	1015
2024 Q1	$7.23K	Buy	+749	New	+$8.68K	﹤0.01%	2214
2023 Q1	–	Sell	-626	Closed	-$10.6K	–	2382
2022 Q4	$10.6K	Hold	626	–	–	﹤0.01%	2267
2022 Q3	$14.2K	Hold	626	–	–	﹤0.01%	2175
2022 Q2	$11.3K	Buy	+626	New	+$11.2K	﹤0.01%	2292
2022 Q1	–	Sell	-2,302	Closed	-$67.5K	–	2451
2021 Q4	$67.5K	Hold	2,302	–	–	﹤0.01%	2655
2021 Q3	$151K	Buy	+2,302	New	+$176K	﹤0.01%	2285
2021 Q2	–	Sell	-2,302	Closed	-$177K	–	2781
2021 Q1	$177K	Hold	2,302	–	–	﹤0.01%	2105
2020 Q4	$203K	Hold	2,302	–	–	﹤0.01%	1925
2020 Q3	$170K	Hold	2,302	–	–	﹤0.01%	1878
2020 Q2	$168K	Buy	2,302 +575	+33%	+$34.9K	﹤0.01%	1923
2020 Q1	$97K	Buy	+1,727	New	+$75.7K	﹤0.01%	2046

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s IGMS Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of IGM Biosciences (IGMS) in Q2 2024, closing a stake of 749 shares — an estimated $7.23K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in IGMS in Q1 2020 and held it in 11 quarters. The position peaked at $203K in Q4 2020. 82 funds tracked by Wall St. Rank hold IGMS as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining IGM Biosciences position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 749 IGM Biosciences shares in Q2 2024, an estimated $7.23K.
Metropolitan Life Insurance Company (MetLife) first reported a position in IGM Biosciences in Q1 2020 and held it in 11 quarters.
Metropolitan Life Insurance Company (MetLife)'s IGM Biosciences position peaked at $203K in Q4 2020.
82 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.